Menarini Asia-Pacific reinvents pharmaceuticals in the region
Collaboration among partners committed to improving the lives of patients with high-quality drugs is critical in the pharmaceutical industry. A. Menarini Asia-Pacific exemplifies this with strong business growth in one of the world's most diversified regions.
Collaboration among partners committed to improving the lives of patients with high-quality drugs is critical in the pharmaceutical industry. A. Menarini Asia-Pacific exemplifies this with strong business growth in one of the world's most diversified regions.
Founded in 2005 through the tripartite joint venture of Quintiles, Temasek and Zuellig Group, the company was originally known as Invida Group. In November 2011, Invida was fully acquired by the Menarini Group, the world's largest Italian biopharmaceutical company with a 130-year heritage and ranked in the top 40 among global pharmaceuticals.
With its regional headquarters in Singapore and the combined strengths of an expanding global portfolio, commercialisation expertise with Asian insights and shareholder experience in more than 100 countries, the company has been growing unabated as it aspires to be among the top 20 multinational pharmaceutical companies in Asia-Pacific within seven years. Menarini Asia-Pacific's annual revenue has been growing more than 20 per cent annually and is poised to top US$400 million this year.
"We have a strong track record as a trusted global business partner, successfully bringing products to market in this region and building profitable relationships that provide a unique, win-win value proposition for pharmaceutical companies to tap into the Asia-Pacific growth story," says John Graham, CEO.
Menarini Asia-Pacific markets an extensive range of products across the prescription and consumer health channels. Its wide range of proprietary and partnered products across multiple therapeutic fields provides solutions to ailments proliferating in the region. Serving as the gateway into key Asia-Pacific health care markets, the company helps big and small enterprises hurdle their products' drug development cycle, clinical research, regulatory approval and lifecycle management.
"Singapore offers many advantages for a regional hub, among others providing stability and an ideal environment to nurture our business and attract good talents," Graham says. "Our relationships with Singapore government agencies and commercial partners based here are really important to us in sustaining our growth trajectory."
Menarini Asia-Pacific works closely with local regulators and health care professionals in ensuring that drug pipelines match prevalent needs. This accounts for the firm's strong regulatory, clinical research, sales and marketing presence across 13 markets, including Southeast Asia, South Korea and China, where it became the first foreign enterprise to enter Wuhan's Biolake. Leveraging on global assets, Menarini Asia-Pacific is also moving on commercialisation prospects from Japanese multinationals and within Japan.
"We build our success around uncompromising integrity in our business dealings across the region and the ability to recognise a product's potential to create demand and thus benefit patients, consumers and physicians," Graham says. "We want good brands that address market needs and invigorate lives. This is our brand promise."
